PharmaDepth

Company profile

HARROW, INC.

NASDAQ:HROWBiotechnology: Pharmaceutical Preparations

Drug pipeline (19)

AssetStageRevenueTrialsStatus
VEVYEapproved$29.4MQ2 202619approved
IHEEZOapproved$15.6MQ2 20260—
BYQLOVIapproved—0—
ECONOPREDapproved—5approved
FLAREXapproved—0—

Revenue is the latest quarter the company reported for that product, from SEC filings; a fourth quarter is the year less nine months when no filing states one. Trial counts are of the product's ingredients, deduplicated by trial, so products sharing an ingredient share trials.

Clinical trials (4)

NCT IDPhaseStatusStartCompletionSponsor nameTitle
NCT07832552phase3enrolling_by_invitation2026-05-252026-12-01Harrow IncA Phase 3 Study Evaluating the Safety and Efficacy of TRIESENCE® (Injectable Suspension) for the Treatment of Ocular Inflammation and Pain After Ophthalmic Surgery
NCT07456826phase4enrolling_by_invitation2026-03-312026-08-01Harrow IncStudy Evaluating the Efficacy and Safety of Chloroprocaine HCl Ophthalmic Gel 3% vs Proparacaine Ophthalmic Solution 0.5% Plus Subconjunctival Lidocaine in Patients Undergoing Intravitreal Injections
NCT05934253phase4completed2023-07-152024-01-15Harrow IncThe Effects of Low Viscosity Chloroprocaine Ophthalmic Gel 3% on the Bactericidal Action of Povidone-Iodine
NCT07588074phase4completed2021-05-012021-06-30Harrow IncTolerability Comparison of Flarex to Lotemax SM

FDA applications (20)

ApplicationApprovedTypeApplicantProducts
NDA 2181582024-03-04NDAHARROW EYE LLC
NDA 2174692023-05-30NDAHARROW EYE LLC
NDA 2162272022-09-27NDAHARROW EYE LLC
NDA 2149652021-06-23NDAHARROW EYE LLC
NDA 2086942017-05-30NDAHARROW EYE LLC